National Health Commission: doing a good job in the prevention and treatment of rare diseases is of great significance to building a healthy China

Beijing October 25 Ma Xiaowei, director of the national health and Health Commission, said at the 2020 China rare diseases conference held on October 24 that there are about 20 million patients with various rare diseases in China, according to data from relevant institutions. The prevention and control of rare diseases is of great significance to improve the health level of the whole people and build a healthy China. < p > < p > Ma Xiaowei said that the National Health Commission, together with relevant departments, issued the first batch of rare diseases catalogue, clarified the concept and scope of rare diseases in China, and defined the management scope; established the national rare disease diagnosis and treatment cooperation network, established the rare disease two-way referral and long-range consultation system; carried out direct reporting of rare disease cases, issued rare disease diagnosis and treatment guidelines, and continued to carry out The training provided a comprehensive policy and measure guarantee for improving the ability of diagnosis and treatment of rare diseases in China. He said that it is necessary to do a good job in the prevention and treatment of rare diseases to promote the in-depth development of medical reform. In the prevention and treatment of rare diseases, there are still some problems in China, such as insufficient diagnostic capacity, unbalanced resource allocation, lack of drugs, high price of some orphan drugs, and low innovation ability of drug research and development. To solve these problems, we need to promote the construction of national regional medical centers, promote hierarchical diagnosis and treatment, improve the drug supply security system, and deepen the reform of medical security system The direction of medical reform development. Ma Xiaowei also pointed out that the etiology of rare diseases is complex, and it is an important opportunity to promote the combination of Chinese medical basis and clinical research to achieve scientific research breakthroughs.